Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: A randomised, double-blind, placebo-controlled trial

The Lancet HIV

Volumn 2, Issue 2, 2015, Pages e52-e63

  Lo, Janet ^a   Lu, Michael T ^a   Ihenachor, Ezinne J ^a   Wei, Jeffrey ^a   Looby, Sara E ^a   Fitch, Kathleen V ^a   Oh, Jinhee ^a   Zimmerman, Chloe O ^a   Hwang, Janice ^a   Abbara, Suhny ^a   Plutzky, Jorge ^b   Robbins, Gregory ^a   Tawakol, Ahmed ^a   Hoffmann, Udo ^a   Grinspoon, Steven K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATININE; FLUORODEOXYGLUCOSE F 18; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; PLACEBO; AMINO ACID; STATINE;

ADULT; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ANOMALY; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MYALGIA; MYOSITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TREATMENT OUTCOME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMPLICATION; CORONARY BLOOD VESSEL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ADULT; AMINO ACIDS; ATHEROSCLEROSIS; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; CORONARY VESSELS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; TREATMENT OUTCOME;

EID: 84923829978     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(14)00032-0     Document Type: Article

References (51)

1. Triant VA, Lee H, Hadigan C, Grinspoon SK Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007, 92:2506-2512.
2. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007, 44:1625-1631.
3. Lohse N, Hansen A-BE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
4. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34.
5. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013, 173:614-622.
6. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010, 24:243-253.
7. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014, 160:458-467.
8. Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013, 208:1737-1746.
9. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012, 308:379-386.
10. Zanni MV, Abbara S, Lo J, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 2013, 27:1263-1272.
11. Kristensen TS, Kofoed KF, Kuhl JT, Nielsen WB, Nielsen MB, Kelbaek H Prognostic implications of nonobstructive coronary plaques in patients with non-ST-segment elevation myocardial infarction: a multidetector computed tomography study. J Am Coll Cardiol 2011, 58:502-509.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
13. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
14. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
15. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004, 147:E18.
16. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014, 58:588-595.
17. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014, 209:1156-1164.
18. Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart 2006, 92:110-112.
19. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009, 50:1611-1620.
20. Raff GL, Abidov A, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. J Cardiovasc Comput Tomogr 2009, 3:122-136.
21. Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation 2004, 109:14-17.
22. Papadopoulou S, Neefjes LA, Garcia-Garcia HM, et al. Natural history of coronary atherosclerosis by multislice computed tomography. JACC Cardiovasc Imaging 2012, 5(3 suppl):S28-S37.
23. Oberoi S, Meinel FG, Schoepf UJ, et al. Reproducibility of noncalcified coronary artery plaque burden quantification from coronary CT angiography across different image analysis platforms. AJR Am J Roentgenol 2014, 202:W43-W49.
24. Schlett CL, Ferencik M, Celeng C, et al. How to assess non-calcified plaque in CT angiography: delineation methods affect diagnostic accuracy of low-attenuation plaque by CT for lipid-core plaque in histology. Eur Heart J Cardiovasc Imaging 2013, 14:1099-1105.
25. Hamirani YS, Zeb I, Pagali SR, et al. Normalization of automatic plaque quantification in cardiac computed tomography (CCT). Int J Cardiol 2011, 146:282-290.
26. Nakazato R, Shalev A, Doh J, et al. Aggregate plaque volume by coronary computed tomography angiography is superior and incremental to luminal narrowing for diagnosis of ischemic lesions of intermediate stenosis severity. J Am Coll Cardiol 2013, 62:460-467.
27. Boogers MJ, Broersen A, van Velzen JE, et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. Eur Heart J 2012, 33:1007-1016.
28. Versteylen M, Kietselaer B, Dagnelie P, et al. Additive value of semiautomated quantification of coronary artery disease using cardiac computed tomographic angiography to predict future acute coronary syndrome. J Am Coll Cardiol 2013, 61:2296-2305.
29. Schuhbaeck A, Dey D, Otaki Y, et al. Interscan reproducibility of quantitative coronary plaque volume and composition from CT coronary angiography using an automated method. Eur Radiol 2014, 24:2300-2308.
30. Kitagawa T, Yamamoto H, Horiguchi J, et al. Characterization of noncalcified coronary plaques and identification of culprit lesions in patients with acute coronary syndrome by 64-slice computed tomography. JACC Cardiovasc Imaging 2009, 2:153-160.
31. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009, 5:49-57.
32. Hoffmann U, Moselewski F, Nieman K, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol 2006, 47:1655-1662.
33. Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007, 50:319-326.
34. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832.
35. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013, 27:563-572.
36. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982, 36:172-177.
37. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008, 300:509-519.
38. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
39. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009, 54:49-57.
40. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011, 203:756-764.
41. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999, 338:479-487.
42. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715-2721.
43. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
44. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014, 370:1702-1711.
45. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
46. Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression-a serial coronary CT angiography study. Atherosclerosis 2013, 231:198-204.
47. Inoue K, Motoyama S, Sarai M, et al. Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc Imaging 2010, 3:691-698.
48. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013, 346:f2610.
49. Dormuth CR Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014, 348:g3244.
50. McComsey GA, Jiang Y, Erlandson KM, Debanne SM. Rosuvastatin improves hip bone mineral density but worsens insulin resistance. Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; March 3-6, 2014. Oral abstract 134.
51. Aberg J, Sponseller CA, Kryzhanovski VA, Kartman CE, Thompson MA. Neutral effects of pitavastatin 4 mg and pravastatin 40 mg on blood glucose and HbA1c levels over 12 weeks: prespecified safety analysis from INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs pravastatin for Dyslipidemia), a phase 4 trial Endocrine Society Conference 2013; San Francisco, CA, USA; Jun 15-18, 2013. Abstr SUN725.